Late Stage Cancer
We have developed this section of our web site as a resource point for people who want to read current articles about Esophageal Cancer. Through the use of Google Alert, the Foundation receives all articles written that indicate the word esophageal cancer in them and deal with Late Stage Cancer. We have reviewed the articles supplied by Google alert and we have copied them into this section of our web site. We have not altered any of the articles and by clicking on the specific article you will see the article from its original source. We have categorized these articles into major topics for ease in reference and explanation.
- Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for patients with T4b esophageal squamous cell carcinoma
- Nivolumab Plus Neoadjuvant Chemoradiation Fails to Enhance pCR Rate in Esophageal/GEJ Adenocarcinoma
- ESOPEC Trial: FLOT Protocol Proves Superior to CROSS Regimen in Locally Advanced Esophageal Cancer
- The Drug Tevimbra Now Approved For Use in Esophageal Cancer– Finally Some Help For Patients In Great Need
- Aspirin Linked to Lower Metastasis in Esophageal, Colorectal Cancers
- FLOT vs CROSS in Resectable GEJ Adenocarcinoma: Which Regimen is Best?
- atients With Esophageal Cancer Have ‘More Options’ With Tevimbra
- FDA Approves Tevimbra, BeiGene’s Treatment for Adults with Unresectable or Metastatic Esophageal Squamous Carcinoma
- Dr Shah on Responses With Pembrolizumab Plus Chemo By PD-1 Status in Esophageal Cancer
- Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma
- Nivolumab Plus Chemotherapy Continues to Deliver Efficacy in Gastric Cancer Treatments
- KEYNOTE-590: Long-term Outcomes of First-line Pembrolizumab, Chemotherapy for Advanced Esophageal Cancer
- Nivolumab Plus Chemotherapy Demonstrates Superior OS in Esophageal/Gastric Cancer
- Shitara and Xu Discuss Potential FDA Approval of Zolbetuximab in CLDN18.2+ Gastric/GEJ Adenocarcinoma
- CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma
- Domvanalimab Regimen Shows Potential in First-Line GI Cancer Treatment
- Opdivo and Stivarga Plus Chemotherapy Improves Outcomes in Certain Gastric Cancers
- Zhen Explores the Role of Immunotherapy in Upper GI Cancers
- Advanced Esophageal Cancer and Immunotherapy
- Pembrolizumab/Chemo Improves Responses But Not EFS in Gastric/GEJ Cancer
- Tislelizumab Plus Chemotherapy Improves Overal Survival in ESCC
- BeiGene-Novartis gastric cancer drug succeeds in late-stage trial
- Claudin 18.2 Represents New Druggable Target for CLDN18.2+/HER2-, Advanced/Metastatic Gastric and GEJ Adenocarcinoma
- Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers
- Keytruda Shines in Phase III Gastric Cancer Trial
- ASCO: Bristol Myers touts 2 Opdivo esophageal cancer wins, but the Yervoy combo comes with a caveat
- Which Chemo-IO Combo is Optimal in First-Line Esophageal Cancer?
- Immunotherapy Combination Selection Is Driven by PD-L1 in Gastroesophageal Cancer
- Bristol Myers Squibb, on a roll, touts 2 Opdivo GI cancer wins—including one earlier in treatment
- Frontline Tislelizumab Plus Chemo Achieves 34% Reduction in Risk of Death in Advanced ESCC
- Novartis’ tislelizumab shows promising survival results in advanced esophageal cancer, Phase 3 data reveals
- New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy
- Mayo Clinic dealing with Palliative Care
- Bevacizumab and Gemcitabine with Cisplatin in Esophageal Cancer
- Tislelizumab Plus Chemotherapy Significantly Improved Overall Survival in First-Line Treatment for Advanced Esophageal Cancer
- Major cancer discovery: new antibody blocks tumor growth and metastasis, hope for new treatment
- Steven Maron, MD, MSc, discusses HER2-positive tumors in esophageal gastric cancers.
- Immunotherapy Hits Its Stride in Esophageal and GEJ Cancers
- Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
- A Phase I Study of TJ033721 Immunotherapy in People with Advanced Pancreatic or Esophagogastric Cancer
- Survival Benefit of IO Added to Standard Chemotherapy in Gastric/GEJ/Esophageal Cancers
- HER2 Expression Drives Treatment Decisions in Gastric/Esophageal Cancers
- Keytruda Shows Hint of Major Added Benefit for Patients With Squamous Cell Carcinoma
- Traditional Chinese Medicine Decoctions Improve Longevity Following Diagnosis with Stage IV Esophageal Squamous Cell Carcinoma: A Retrospective Analysis
- Global Top 10 Cancer Antibodies By Sales 2021
- Pembrolizumab Plus Chemotherapy Represents New SOC for Esophageal Cancer/ GEJ Adenocarcinoma
- Docetaxel regimen extends OS as neoadjuvant therapy for locally advanced esophageal cancer
- Sugemalimab Demonstrates Overall Survival Benefit in Stage IV Non-Small Cell Lung Cancer
- CStone announced two key phase 3 registrational clinical trials of sugemalimab completed patient enrollment
- Immune Checkpoint, VEGFR Inhibitor Combo Effective in Advanced Esophageal Cancer
- Immunotherapy Approvals Propel the Future of GI Cancer Treatment
- Role of surgery in the management of synchronous metastatic esophageal cancer
- ESMO 2021: Cancer Research and Drug Development Highlights
- Nivolumab/Ipilimumab Combo Misses Mark while Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer
- Guideline Rapid Update Provides New Direction on the Care of Patients With Residual Disease in Locally Advanced Esophageal Cancer
- Innovent Announces Sintilimab in Combination with Chemotherapy Meets the Primary Endpoint of Overall Survival in the Phase 3 ORIENT-16 Study for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Gastroenterologist gets patent for polypectomy device->-> View it–> https://www.newkerala.com/news/2021/112353.htm
- For stomach cancer patients, a regionalized cancer care program can improve survival
- Bristol Myers Says EC Approves Opdivo as Adjuvant Treatment in Esophageal or Gastroesophageal Junction Cancer
- Tiragolumab/Atezolizumab Demonstrate Promising Preliminary Activity in Metastatic Esophageal Cancer
- Tiragolumab-Atezolizumab Combo Shows Preliminary Clinical Activity in Metastatic Esophageal Cancer
- Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Third-Line Gastric Cancer in the US
- New Potential Immunotherapy Treatment Options in Advanced Esophageal Squamous Cell Carcinoma
- Bristol Myers Touts Opdivo Win in Esophageal Cancer, But Yervoy-Opdivo Combo Comes with Caution
- Individualized Treatment May Improve Outcomes in Gastroesophageal Cancer
- Personalized, Adaptable Treatment Strategies May Improve Survival in Metastatic Gastroesophageal Cancer
- FDA approves first-line Keytruda-based regimen for advanced HER2-positive gastric cancer
- Immunotherapy Regimen Continues to Improve GI Treatment
- PD-1 Regimens Lead Charge Against Gastrointestinal Cancers
- Progressive, locally advanced unresectable, and metastatic esophageal and gastric cancer: Approach to later lines of systemic therapy
- Gender Differences in Treatment Allocation and Survival of Advanced Gastroesophageal Cancer: a Population-Based Study
- CORRECTING and REPLACING Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal…
- Drug Could Be a ‘Game-Changer’ in Fighting Esophageal Cancers
- Immunotherapy Makes Waves in Gastroesophageal and Gastric Cancers
- FDA Approves Pembrolizumab for Advanced Esophageal/GEJ Cancer
- FDA Approves Keytruda With Chemotherapy for Esophageal, Gastroesophageal Cancers
- Opdivo with Chemotherapy Treatment Under Priority Review by FDA Shows Promise for Patients with Advanced Gastrointestinal Cancers
- Tislelizumab extends OS in advanced esophageal cancer
- BeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma
- Hope for Stomach Cancer and Esophageal Cancer Education Foundation have joined to provide a monthly support for stage 4
- FDA grants priority review to Opdivo for gastric, esophageal cancer indications
- Trastuzumab Deruxtecan Brings HER2 Targeted Therapy to 3L HER2+ Advanced Gastric cancer/GEJ Cancers
- FDA grants priority review to Keytruda-chemotherapy regimen for esophageal cancer
- KEYNOTE-590 Trial: Pembrolizumab Improves OS in Esophageal Cancer
- Second-Line Pembrolizumab Improves Overall Survival vs Chemotherapy in Patients with Advanced Esophageal Cancer
- Post-surgery Opdivo Found to Reduce Risk of Recurrence in High-risk Bladder Cancer
- Opdivo Combo Found to Extend Survival in Advanced Stomach, Esophageal Cancers
- For Esophageal Cancer, Immunotherapy Likely to Play Larger Role
- Keytruda Combo Shown to Extend Survival in Advanced Esophageal, GEJ Cancers
- Nivolumab may be ‘new standard’ in esophageal, gastroesophageal junction cancers
- Does Medicare Cover Immunotherapy?
- Opdivo-chemo combo improves survival in gastric, esophageal cancer
- Pembrolizumab Plus Chemotherapy Enters Frontline Treatment Landscape of Advanced Esophageal Cancer
- CRI Virtual Immunotherapy Patient Summit
- New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck’s Commitment to Advancing Cancer Research and Care
- Trending News on Targeted Oncology, Week of August 21, 2020
- Merck : Phase 3 Study Of KEYTRUDA – Chemotherapy On Metastatic Esophageal Cancer Meets Main Goal
- Pembrolizumab regimen extends survival in advanced esophageal cancer
- Geoffrey Ku, MD, Discusses New Non-Immunotherapy Targets and Therapies in GI Cancer
- Nivolumab Plus Chemotherapy Improves Survival Outcomes in Gastric and Esophageal Cancers